Результаты поиска

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… de Alta Especialidad,, Guadalupe, Mexico; 13 General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic; 14 The Federal State Autonomous Institution “National Medical Research Center for Children’s Health” of the Ministry of Health of the Russian Federation, Moscow …

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials eva

Совпадение в полном тексте источника
… Sendai virus strain Moscow (SeVM) has been of particular interest for tumor treatment since the 1960s when chicken-embryo adapted strain was used as an alternative therapy for progressive tumor cases. … Poleznye Dlya Ogranizma Nepatogennye Shtammy Enterovirusov: Profilakticheskoe i Lechebnoe ikh Primenenie (Useful Nonpathogenic Enterovirus Strains: Preventive and Therapeutic Applications) Meditsina; Moscow, Russia: 1988. …

Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

BACKGROUND: Healthy life expectancy (HALE) and disability-adjusted life-years (DALYs) provide summary measures of health across geographies and time that can inform assessments of epidemiological patterns and health system performance, help to prioritise investments in research and development, and monitor progress toward the Sustainable Development Goals (SDGs). We aimed to provide updated HALE and DALYs for geographies worldwide and evaluate how disease burden changes with development. METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 20

Concept of natural genome reconstruction.Part 5. Analysis of changes in the lifespan of old animals after reinfusion of bone marrow cells derived from old animals and treated with hDNAgr in combination with recombinant human angiogenin.

Two series of tests were performed, on mice and rats, to assess the lifespan of old animals reinfused with bone marrow cells from old animals treated with fragmented human DNA (hDNAgr), recombinant human angiogenin, and both preparations together. Animals reinfused with untreated bone marrow cells from old animals or bone marrow cells from young animals were used as comparison groups. Using both outbred mice and CBA/Lac mice, no significant increase in the lifespan of animals reinfused with bone marrow cells treated with the hDNAgr was found compared with the group of mice reinfused with untre

Совпадение в полном тексте источника
… Moscow: Mir Publ., 1984 (in Russian) Mikheev R.K., Andreeva E.N., Grigoryan O.R., Sheremetyeva E.V., Absatarova Y.S., Odarchenko A.S., Opletaeva O.N. Molecular and cellular mechanisms of ageing: modern knowledge (literature review). … Bryukhovetskiy, Clinical Hospital ‘‘NeuroVita’’, Moscow, Russia S.S. Bogachev, Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia …

Всемирный конгресс по болезням остеопороза, остеоартрита и мускулоскелета 2025).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.

Lessons learnedResults are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease.MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity.Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline.MBC-11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development.BackgroundMBC-11 is a first-in-class conju

Совпадение в полном тексте источника
… (Moscow, Russia) for clinical development. MBC‐11 active pharmaceutical ingredient was manufactured by Johnson Matthey Pharma Services (Devens, MS). Phase II work is planned for in a multisite open label study in Russia; with success, continued international development will be pursued. …

15th Конгресс Европейской ассоциации клинической фармакологии и терапии (ЕАКПТ)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Абстрактный сборник ISEV2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ISEV2021 Abstract Book

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma-Diagnostic Difficulties.

BackgroundCardiac AL amyloidosis as a complication of multiple myeloma (MM) is a formidable life-threatening condition. The first-line therapy for both MM and systemic AL amyloidosis is proteasome inhibitors (PIs). Unfortunately, the use of PIs may lead to cardiovascular toxicity development, which requires specific cardio-oncology supervision.Case reportA 57-year-old woman was admitted to a university hospital with clinical manifestation of progressive chronic heart failure. The patient had hypertension and no history of diabetes mellitus, myocardial infarction (MI), stroke, and arrhythmias.

Совпадение в полном тексте источника
… Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The patients/participants provided their written informed consent to participate in this study. …

Резюме: 31 Европейский конгресс патологии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Esid 2014 oral presentations.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Laboratory Research Department, Belarusian Research Center for Pediatric Oncology Hematology and Immunology, Minsk, Belarus 29 Department of Immunology, University Children's Hospital, Skopje, Macedonia 30 Immunology, Federal Research and Clinical Center for Pediatric Hematology Oncology and Immunology, Moscow …

The International Headache Congress - IHS and EHF joint congress 2021 : Virtual. 8-12 September 2021.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… University of Modena and Reggio Emilia, Modena, Italy; 11 Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom; 12 Ludwig Maximilians University, Munich, Germany; 13 Azienda USL di Reggio Emilia, Reggio Emilia, Italy; 14 University of Parma, Parma, Italy; 15 Sechenov University, Moscow …

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone в t()11;14)-Positive replaped/recractory multieloma: первичные результаты случайного исследования, этап III CANOVA.

ЦЕЛЬ: Венетоклакс, устный перевод BCL-2 ингибитор, имеет эффективность в t(11;14)-положительное повторное/восстановительное несколько миэлом (RRMM), которое усиливается дексаметазоном, который поощряет BCL-2 Зависимость. МЕТОДЫ: случайная, открытая маркировка, этап III исследования CANOVA (индивидуальный идентификатор Clinical Processors.gov): NCT03539744) зачисленные взрослые, имеющие t()11;14) - положительный RRM, получивший ≥2 предыдущие линии терапии. Пациенты были назначены по случайному назначению ( " .1::1) на венетоклакс-дексаметазон или помалидомид-дексазон до прогресса или невын

Совпадение в полном тексте источника
… Novaya Klinika Rachel Brown | Manchester University NHS Foundation Alberto Rocci | Manchester University NHS Foundation Shaji Kumar | Mayo Clinic Rochester Prashant Kapoor | Mayo Clinic Rochester Krina Patel | MD Anderson Cancer Center Shigeki Ito | Iwate Medical University Hospital Vladimir Vorobyev | Moscow … State Budgetary Healthcare Institution Vera Zherebtsova | Moscow State Budgetary Healthcare Institution Shinsuke Iida | Nagoya City University Hospital Bing Chen | Nanjing Drum Tower Hospital Wee Joo Chng | National University Hospital Kristian Bowles | Norfolk and Norwich University Hospital Niels …

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

BackgroundMelphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown.MethodsChromatin structure, transcriptional activity and DNA damage response signals were examined following ex vivo treatment with melphalan of both malignant bone marrow plasma cells (BMPCs) and peripheral blood mononuclear cells (PBMCs) of MM patients, responders (n=57) or non-responders (n=28) to melphalan therapy. PBMCs from healthy controls (n=25) were also included in the study.Re

Совпадение в полном тексте источника
… likely that additional mechanisms (that is, repair of DNA lesions downstream of melphalan-DNA N -alkylpurines, such as ICL and double-strand breaks ( Gourzones-Dmitriev et al , 2013 ), defects in drug transport systems resulting in reduced drug uptake ( Tew, 1994 ) and increased binding to glutathione ( Moscow … Moscow JA, Swanson CA, Cowan KH. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993;68:732–737. doi: 10.1038/bjc.1993.419. Palumbo A, Anderson K. Multiple myeloma. …

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Fighting trafficking of falsified and substandard medicinal products in Russia.

BACKGROUND: The trafficking of falsified and substandard medicinal products is a global socio-economic problem, which poses a serious threat … t service providers on cessation of activities at these sites was issued [1].On 26-28 October 2011, Moscow hosted an international high-level conference on counterfeiting of medicinal products, which was attended by more than 750 professionals in the field of law and pharmacy from different countries, including USA, China, countries of the European Counc …

Устные бесплатные бумажные сессии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Rotin * Botkin Hospital, Dept. of Pathology, Moscow, Russia Objective: Currently there is a priority for searching of new selective cellular-target anticancer drugs for ampullary carcinoma (AC). Targeting therapy requires information about mutational status of cellular target. … Shubin * Botkin Hospital, Dept. of Pathology, Moscow, Russia Objective: Most researches are currently focused on epithelium-stroma relationship that plays an important role in epithelial tumour progression towards to de-differentiated phenotype. Method: 100 patients with PDAC. …

ПРЕНАТАЛЬНАЯ УЛЬТРАЗВУКОВАЯ ДИАГНОСТИКА ВРОЖДЁННЫХ АНОМАЛИЙ ПЛОДА: СОВРЕМЕННЫЕ ТРЕНДЫ И СТАНДАРТЫ

В статье рассматриваются современные подходы к пренатальной ультразвуковой диагностике врождённых аномалий плода с позиций актуальных международных и национальных стандартов. Пренатальная ультразвуковая диагностика (ПУЗД) является ключевым инструментом в раннем выявлении структурных и функциональных пороков развития, что позволяет своевременно определить прогноз беремен.ности, выбрать оптимальную тактику ведения и, при необходимости, направить пациентку в специализированный перинатальный центр. Анализируются современные тенденции в развитии ультразвуковых технологий, включая применение высокор

Совпадение в полном тексте источника
… Moscow. 2020;1(37):33-36. 14. Khamidov OA, Khodzhanov IYu, Mamasoliev BM, Mansurov DSh, Davronov AA, Rakhimov AM The Role of Vascular Pathology in the Development and Progression of Deforming Osteoarthritis of the Joints of the Lower Extremities (Literature Review). …